|
|
???tair.name??? >
???browser.page.title.author???
|
"lanzinger s"???jsp.browse.items-by-author.description???
Showing items 1-2 of 2 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國家衛生研究院 |
2023-08-31 |
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
|
Vistisen, D; Carstensen, B; Elisabetta, P; Lanzinger, S; Tan, ECH; Yabe, D; Kim, DJ; Sheu, WHH; Melzer-Cohen, C; Holl, RW; Núñez, J; Ha, KH; Halvorsen, S; Langslet, G; Karasik, A; Nyström, T; Niskanen, L; Guleria, S; Klement, R; Carrasco, M; Foersch, J; Shay, C; Koeneman, L; Hoti, F; Farsani, SF; Khunti, K; Zaccardi, F; Subramanian, A; Nirantharakumar, K; EMPRISE EU and East Asia Study Group |
| 國立成功大學 |
2023 |
Diabetes care practices and outcomes in 40.000 children and adolescents with type 1 diabetes from the SWEET registry during the COVID-19 pandemic
|
Chobot, A.;Lanzinger, S.;Alkandari, H.;Todd, Alonso G.;Blauensteiner, N.;Coles, N.;De, Sanctis L.;Mul, D.;Saboo, B.;Smart, C.;Tsai, M.-C.;Zabeen, B.;Dovc, K. |
Showing items 1-2 of 2 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
